Data on study characteristics, patient demographics, and GLP-1 agonist use were collected
The trial enrolled 281 participants across 42 research and healthcare centers in the United States, randomized to once-weekly subcutaneous retatrutide (0.5, 4, 8, or 12 mg), once-weekly subcutaneous dulaglutide 1.5 mg (active comparator), or placebo, over a 36-week treatment period
While many people recognize L-carnitine for its role in fat metabolism, men using TRT are often interested in it for a different reasonits potential to enhance androgen receptor activity
Most people experience appetite reduction within the first week but don't see scale weight loss until week 34 or later
Pregnant or breastfeeding individuals and minors should avoid these therapies, and anyone considering peptides must complete a thorough medical evaluation first